Literature DB >> 18408829

[Macula study in Stargardt's disease].

Otacílio de Oliveira Maia1, Walter Yukihiko Takahashi, Tiago Eugênio Faria e Arantes, Raquel Barbosa Paes Barreto, João Lins de Andrade Neto.   

Abstract

PURPOSE: To evaluate de macular structural damage in Stargardt's disease by optical coherence tomography, correlating with visual acuity and disease duration.
METHODS: Patients with Stargardt's disease were included and submitted to visual acuity (logMAR) measurement and complementary examinations performed were color fundus photographs, fluorescein angiography and optical coherence tomography. All cases were reexamined for diagnostic confirmation and the duration of symptoms was determined. The control group was composed of the same number of subjects, matched by sex and age, without any ophthalmologic alteration.
RESULTS: The sample was composed of 22 patients (44 eyes) with Stargardt's disease, 11 (50%) males and 11 (50%) females. The duration of the disease varied from 3 to 21 years (mean of 11.4 +/- 5.3 years). The groups did not show significant differences in age (p= 0.98) and sex. Concerning the macular thickness in optical coherence tomography, the variation in the study group differed significantly from the control group, presenting smaller values of thickness (p<0.001). There was negative and significant correlation between the duration of disease and the macular thickness assessed by optical coherence tomography (r=-0.57 and p=0.005). There was positive correlation between the duration of the disease and the visual acuity (r=0.50 and p=0.0167) and negative correlation between the visual acuity and the macular thickness in optical coherence tomography (r=-0.83 and p=0.0001).
CONCLUSION: It was evidenced that patients with Stargardt's disease have a thinner macular thickness when compared to normal subjects, and this reduction is related to the duration of symptoms of the disease. Additionally, the thickness and also the duration of the disease influence the visual prognosis of the patients.

Entities:  

Mesh:

Year:  2008        PMID: 18408829     DOI: 10.1590/s0004-27492008000100002

Source DB:  PubMed          Journal:  Arq Bras Oftalmol        ISSN: 0004-2749            Impact factor:   0.872


  2 in total

1.  Intravitreal Use of a Bone Marrow Mononuclear Fraction (BMMF) Containing CD34+ Cells in Patients with Stargardt Type Macular Dystrophy.

Authors:  Carina Costa Cotrim; André M Vieira Messias; Rodrigo Jorge; Rubens Camargo Siqueira
Journal:  Stem Cells Int       Date:  2020-12-10       Impact factor: 5.443

2.  Do you know this syndrome?

Authors:  Renata Hubner Frainer; Luciana Boff de Abreu; Giselle Martins Pinto; André Vicente Esteves de Carvalho; Luana Pizarro Meneghello
Journal:  An Bras Dermatol       Date:  2013 Jan-Feb       Impact factor: 1.896

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.